Browsing Tag
Solengepras
1 post
Cerevance advances non-dopaminergic Parkinson’s strategy after positive solengepras Phase 3 trial
Cerevance’s solengepras wins Phase 3 in Parkinson’s disease, opening an FDA path and a potential first-in-class GPR6 commercial opportunity.